Considering KMT2D’s role in the PI3K/AKT/SOX2 axis in NSCLC, which affects tumor growth, combined targeted therapy of KMT2D and PI3K may offer new treatment possibilities for LSCC. This evidence concerns the gene AKT1 and neoplasm.